Daily Newsletter

14 September 2023

Daily Newsletter

14 September 2023

Regulus concludes enrolment in ADPKD therapy trial’s second cohort

Patients will receive 2mg/kg of RGLS8429 or placebo every other week for three months.

September 14 2023

Regulus Therapeutics has concluded enrolment in the second cohort of the Phase Ib multiple ascending dose (MAD) trial of RGLS8429 to treat autosomal dominant polycystic kidney disease (ADPKD).

The placebo-controlled, double-blind study is designed to assess the pharmacokinetics, pharmacodynamics, tolerability, and safety of the miR-17 inhibitor RGLS8429 in adults with ADPKD.

It will assess treatment with RGLS8429 across three different dose levels, including measurement of changes in cyst architecture, height-adjusted total kidney volume, polycystins and overall function of the kidney.

Patients will receive 2mg/kg of RGLS8429 or placebo every other week for three months.

Regulus Therapeutics CEO Jay Hagan said: “I am looking forward to watching this cohort progress through the study as well as sharing topline data from our first cohort in the coming weeks.”

Following a review of complete available cohort 2 safety data, Regulus plans to initiate dosing the third cohort in October this year.

The favourable safety and PK profile of RGLS8429 were demonstrated in the Phase I single ascending dose study with no serious adverse events reported.

Plasma exposure was also found to be linear across the four tested doses and showed similar PK data as the first-generation compound, RGLS4326.

A chronic toxicity study of RGLS8429 carried out in mice for 27 weeks also demonstrated no toxicity at any dose level up to the top dose of 300mg/kg.

Significant opportunities and risks for disease-modifying therapies (DMTs) entering the PD market

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close